CA-CEQUENCE-SECURITY
15.12.2021 15:02:05 CET | Business Wire | Press release
Cequence Security , the leader in API security, today announced it has closed $60 million in Series C funding led by new investor Menlo Ventures. Additional participation comes from new investors ICON Ventures, Telstra Ventures and HarbourVest Partners. Existing investors Shasta Ventures, Dell Technologies Capital and T-Mobile Ventures also participated in this funding round. The latest round of funding brings total investment in the company to $100 million.
This new financing comes on the heels of record growth for Cequence , driven by advancements in business applications in response to the COVID-19 pandemic. Across multiple industries, companies have accelerated their digital transformation projects and deployed a growing number of new APIs, but in the process, they have overlooked traditional security reviews and governance best practices.
Cequence’s API security solution is the most comprehensive platform on the market and its success in protecting 2 billion API transactions per day is unmatched by competitors. Cequence works tirelessly to help organizations protect their APIs and their businesses with API inventory tracking, risk assessment and threat prevention—all performed natively and at runtime.
This hard work has proven fruitful, as Cequence services over 85 brands worldwide, including several Fortune 500 and 100 companies in markets ranging from banking and beauty, to retail and consumer mobile apps.
VP Analyst at Gartner, Mark O’Neill and Jeremy D'Hoinne, emphasizes in 2021 Gartner® “Hype Cycle™ for Application Security, 2021” report .
“Many organizations lack visibility of their APIs, as many APIs are used as part of web or mobile applications and not published directly. This means that a key requirement of API threat protection is API discovery, since, as every security professional knows, you can’t secure what you don’t know.” 1
“As an active cybersecurity investor, I’ve looked at countless API security vendors, but I’m placing my bets on Cequence—as is the market. Among their impressive roster of customers, you’ll find several household names and Fortune 500 organizations, which speaks to their ability to meet the API protection demands of the largest and most demanding enterprise businesses,” said Venky Ganesan, partner at Menlo Ventures. “Part of the appeal is superior product architecture. Cequence can stand alone: It is the only solution that provides visibility and inline response mitigation to attacks on APIs. It’s the only solution out there that doesn’t need to signal other products for mitigation.”
The funding will support new enhancements to Cequence’s API security solutions and the expansion of its product offerings. It will also help the company break into new regions in the United States and Europe, as well as new markets in Asia and Australia. In turn, Cequence will be looking to aggressively hire and grow its team within these geographies. As part of the transaction, Venky Ganesan of Menlo Ventures will also join the company’s board.
“From social networks to online shopping and financial services, so many aspects of our lives and digital experiences are tied to APIs. That’s why it’s critical to be able to manage your entire API inventory to address security gaps and protect against rising API threats that may lead to fraud and data loss,” said Larry Link, CEO of Cequence Security. “We’re thrilled that our new and existing investors recognize this growing market need and are eager to support our mission to protect organizations—and users—in this digital-first world.”
To learn more about Cequence’s API visibility and protection capabilities or to schedule a demo, visit: https://www.cequence.ai/
1 Gartner, “Hype Cycle™ for Application Security, 2021, Joerg Fritsch, 12 July 2021.
Gartner Disclaimer:
GARTNER and HYPE CYCLE are a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission.
About Cequence Security
Organizations trust Cequence Security to protect their APIs and web applications with the most effective and adaptive defense against online fraud, business logic attacks, exploits and unintended data leakage; which enables them to remain resilient in today’s ever-changing business and threat landscape. Cequence is the only API Security Platform offering that unifies API discovery, inventory tracking, risk analysis and remediation with proven, real-time threat protection against ever evolving online attacks. Learn more at www.cequence.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
